In 9 randomized clinical trials of alirocumab including 2482 patients, 3.4% of patients on alirocumab reported treatment-emergent diabetes or worsening of preexisting diabetes compared to 3.1% of patients on placebo. Laboratory tests found that at 52 weeks, patients on alirocumab on average saw a 0.16 mmol/L increase in fasting glucose levels and a 0.10% increase in hemoglobin A1c levels compared to placebo.

1. Data abstractedfrom ACC15 AbstractA1363, PooledSafetyandAdverseEventsinNine Randomized,
Placebo-Controlled,Phase 2andPhase 3 Clinical Trialsof Alirocumab. J Am Coll Cardiol. 2015;
65(10_S). doi: 10.1016/S0735-1097(15)61363-8.
Alirocumab Placebo
N=2482 N=1277
Adverse events,%(n)
Anytreatment-emergent
diabetesorworseningof
preexistingdiabetes
3.4 (83) 3.1 (40)
Otherclinical laboratorydata.
Week52 change frombaseline.
N=2318 N=1174
Fastingglucose,mmol/L,mean
(SD)
0.16 (1.52) 0.13 (1.64)
HemoglobinA1c%,mean(SD) 0.10 (0.66) 0.07 (0.54)